Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support
Journal of Intensive Care Medicine · 2023-05 · 38 (5) · 464-471
DOI: 10.1177/08850666221145864 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Intensive Care Medicine, online erschienen am 15.12.2022. Verfasst von Patrick M Wieruszewski und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Hypotension, Shock, Heart Failure. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Patients supported on mechanical circulatory support devices experience vasodilatory hypotension due to high surface area exposure to nonbiological and non-endothelialized surfaces. Angiotensin II has been studied in general settings of vasodilatory shock, however concerns exist regarding the use of this vasopressor in patients with pre-existing cardiac failure. The objective of this study was to assess the systemic and central hemodynamic effects of angiotensin II in patients with primary cardiac or respiratory failure requiring treatment with mechanical circulatory support devices.
Methods
Multicenter retrospective observational study of adults supported on a mechanical circulatory support device who received angiotensin II for vasodilatory shock. The primary outcome was the intraindividual change from baseline in mean arterial pressure (MAP) and vasopressor dosage after angiotensin II.
Results
Fifty patients were included with mechanical circulatory devices that were primarily used for cardiac failure (n = 41) or respiratory failure (n = 9). At angiotensin II initiation, the norepinephrine equivalent vasopressor dosage was 0.44 (0.34, 0.64) and 0.47 (0.33, 0.73) mcg/kg/min in the cardiac and respiratory groups, respectively. In the cardiac group, MAP increased from 60 to 70 mmHg (intraindividual P < .001) in the 1 h after angiotensin II initiation and the vasopressor dosage declined by 0.04 mcg/kg/min (intraindividual P < .001). By 12 h, the vasopressor dosage declined by 0.16 mcg/kg/min ( P = .001). There were no significant changes in cardiac index or mean pulmonary artery pressure throughout the 12 h following angiotensin II. In the respiratory group, similar but nonsignificant effects at 1 h on MAP (61-81 mmHg, P = .26) and vasopressor dosage (decline by 0.13 mcg/kg/min, P = .06) were observed.
Conclusions
In patients requiring mechanical circulatory support for cardiac failure, angiotensin II produced beneficial systemic hemodynamic effects without negatively impacting cardiac function or pulmonary pressures. The systemic hemodynamic effects in those with respiratory failure were nonsignificant due to limited sample size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
- Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
- Multidisciplinary Epidemiology and Translational Research in Intensive Care (METRIC), Mayo Clinic, Rochester, MN, USA.
- Department of Medicine, 1371Emory University, Emory Critical Care Center, Atlanta, GA, USA.
- Department of Anesthesiology and Critical Care Medicine, 43989George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
- Department of Anesthesiology, Section on Critical Care Medicine, Perioperative Outcomes and Informatics Collaborative, Wake Forest School of Medicine, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC,…
ORCID-Profile: Patrick M Wieruszewski, Erin F Barreto, Jonathan H Chow
Förderung
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Wieruszewski, P. M., Seelhammer, T. G., Barreto, E. F., Busse, L. W., Chow, J. H., Davison, D. L., Gaglani, B., Khanna, A. K., Ten Lohuis, C. C., Mara, K. C., & Wittwer, E. D. (2023). Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support. Journal of Intensive Care Medicine, 38(5), 464-471. https://doi.org/10.1177/08850666221145864
Vancouver
Wieruszewski PM, Seelhammer TG, Barreto EF, Busse LW, Chow JH, Davison DL, et al. Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support. Journal of Intensive Care Medicine. 2023;38(5):464-471. doi:10.1177/08850666221145864
BibTeX
@article{Wieruszewski2023,
author = {Wieruszewski, Patrick M and Seelhammer, Troy G and Barreto, Erin F and Busse, Laurence W and Chow, Jonathan H and Davison, Danielle L and Gaglani, Bhavita and Khanna, Ashish K and Ten Lohuis, Caitlin C and Mara, Kristin C and Wittwer, Erica D},
title = {Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support},
journal = {Journal of Intensive Care Medicine},
year = {2023},
volume = {38},
number = {5},
pages = {464--471},
doi = {10.1177/08850666221145864}
}
EUVIMED